Perspectives of XXXX Antagonist in Treatment of Obesity: Experience of RIO-Asia.

@entity1 @entity6 @entity28 @entity6510 @entity1674 @entity165 @entity351
@entity351 , a selective cannabinoid-1 ( @entity6510 ) receptor antagonist, has been shown to reduce weight and enhance improvements in cardiometabolic risk parameters in Western populations. This study assessed these effects of @entity351 in Asian population. A total of 643 @entity1 (BMI 25   kg/m(2) or greater without @entity6 ) from China, Republic of Korea, and Taiwan were prescribed a hypocaloric diet (600   kcal/day deficit) and randomized to @entity351 20   mg (n = 318) or placebo (n = 325) for 9months. The primary efficacy variable was weight change from baseline after 9 months of treatment. Results showed that @entity351 group lost more weight than placebo, (LSM    SEM of -4.7    0.3   kg vs. -1.7    0.3   kg, P < .0001). The 5% and 10% responders were 2 or 3 folds more in the @entity351 group (53.0% vs. 20.0% and 21.5% vs. 5.7%, resp.) (P < .0001). @entity351 also significantly increased HDL- @entity165 , decreased @entity1674 and waist circumference,by 7.1%, 10.6%, and 2.8   cm, respectively (P < .0001). This study confirmed the comparable efficacy and safety profile of @entity351 in Asian population to Caucasians. Owing to the recent suspension of all the @entity6510 antagonists off the pharmaceutical market for weight reduction in Europe and USA, a perspective in drug discovery for intervening peripheral @entity6510 receptor in the management of @entity28 is discussed.
